ReviR Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ReviR Therapeutics, Inc. - overview
Established
2021
Location
Brisbane, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and established in 2021, ReviR Therapeutics is a research and development of a new drug company that focuses on target RNA small molecule drugs field. The company has an additional office in Silicon Valley. The company's core team members are from medical corporations, such as Gilead Sciences, AbbVie, Invitae, who engaged in drug discovery, computational chemistry, and computational biology for nearly 20 years. The co-founder as well as the CEO, Peng Yue, was a director of Computational Biology at AbbVie/Stemcentrx.
In July 2024, ReviR Therapeutics raised USD 30 million in series A funding. ReviR Therapeutics established voyageR™ AI platform that developed target small molecule drugs to treat tumour, rare diseases. The platform takes the technologies of artificial intelligence algorithms and genes sequencing to analyse structure of RNA. The drugs can be used to treat tumours and other rare diseases.
The company generates revenue by developing and providing targeted RNA small molecule drugs. The company will build the AI drug development platform VoyageR, and advance the preclinical and clinical development of existing pipelines related to neurological diseases such as Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
Current Investors
CDH Investments, 5Y Capital, Tiantu Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT, Pharmaceuticals
Website
www.revirtx.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.